ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC grew its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMAFree Report) by 19.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,424 shares of the biotechnology company’s stock after acquiring an additional 23,127 shares during the period. Campbell & CO Investment Adviser LLC owned about 0.06% of ADMA Biologics worth $648,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Sawgrass Asset Management LLC acquired a new position in ADMA Biologics during the 3rd quarter worth $55,000. DekaBank Deutsche Girozentrale acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at about $58,000. AJOVista LLC acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $77,000. Oxford Asset Management LLP acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $83,000. Finally, Algert Global LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at about $80,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 49,887 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $6.01, for a total transaction of $299,820.87. Following the sale, the director now directly owns 2,527,500 shares in the company, valued at approximately $15,190,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 639,895 shares of company stock worth $3,927,169 in the last ninety days. 3.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ADMA. Mizuho lifted their price target on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, May 10th. HC Wainwright lifted their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th. Cantor Fitzgerald lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Finally, Raymond James lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, ADMA Biologics currently has an average rating of “Buy” and an average target price of $10.50.

Read Our Latest Stock Analysis on ADMA Biologics

ADMA Biologics Trading Down 1.0 %

Shares of NASDAQ:ADMA opened at $10.47 on Friday. The company has a market cap of $2.43 billion, a PE ratio of -523.50 and a beta of 0.48. The company’s 50-day moving average price is $7.74 and its 200 day moving average price is $5.96. ADMA Biologics, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $10.85. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03. The firm had revenue of $81.90 million for the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics’s quarterly revenue was up 43.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.03) EPS. Sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.35 earnings per share for the current year.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Stories

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.